alexa Febuxostat May Slow Renal Decline in Hyperuricemic CKD Patients

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Febuxostat May Slow Renal Decline in Hyperuricemic CKD Patients

Febuxostat, which reduces production of uric acid, may slow renal function decline in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia, according to researchers. Patients treated with the uric acid-lowering drug were less likely to experience a greater than 10% decline in eGFR than placebo recipients.

A Study with 93 patients with CKD stages 3 and 4 and asymptomatic hyperuricemia to receive 40 mg of febuxostat (45 patients) or placebo (48 patients) once daily for 6 months. Patients were followed up for 6 months to evaluate changes in eGFR. The primary study outcome was the proportion of patients showing a greater than 10% decline in estimated glomerular filtration rate (eGFR) from baseline.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top